Aim 4 Sample Clauses

Aim 4. To determine the role of the ASFMR1-encoded protein in fragile X syndrome ASFMR1, an antisense gene overlapping the FMR1 locus, has been proposed to play a role in the etiology of fragile X syndrome, possibly due to the absence of the ASFMR1-encoded protein. To determine if the ASFMR1 protein is essential for normal cognitive function, we looked for sequence variants in both developmentally delayed and control males that would alter the function of the ASFMR1 protein. This application of the dataset generated in Aim 3 extended our findings to a second candidate gene for intellectual disability.

Aim 4. The Division of Biostatistics, the Core, and the PSMG provide support for this goal.

Aim 4. Time to first hospital readmission within 30 days

Aim 4. To create mentoring programs that maximize advancing trainees toward academic careers through: (a) intensive mentoring, (b) close monitoring of trainee progress and (c) implementing retention strategies; and (d) tracking and evaluating the quality and outcomes of the graduates of these programs

Aim 4. Quantitative health disparities research is a growing field and we anticipate that the proposed Center will allow UM to further deepenour foothold in this arena. We will look to formalize quantitative health disparities research and education by producing research papers, developing new software modules for wider usage of methods that we will develop and developing new training programs relating to issues in quantitative health disparities research. We will begin building our curriculum based on our plans in the already submitted T32 training grant application in quantitative epidemiology and biostatistics with a slant towards quantitative health disparities.

Aim 4. To determine whether methylphenidate treatment for ADHD is associated with a statistically significant increase in long-term (> 1 year) risk of negative effects on: the rate of growth (i.e. height and weight) and of pubertal maturation. According to international guidelines, treatment for ADHD is based on a multimodal approach that combines behavioural and pharmacological treatment.52,53,12 The first choice medication for ADHD and the most frequently used treatment for ADHD in Europe is methylphenidate.36 Positive effects of stimulants are supported by numerous studies with clear improvements in the core symptoms of hyperactivity, impulsivity and inattention.54 However, these improvements can be accompanied by common mild and transient different side effects (sleeplessness, nervousness, reduced appetite, headache, abdominal pain, changes in blood pressure and heart rate) and several less common effects including reduced weight gain and growth reduction with prolonged use.55,56,57 Although many studies have monitored changes in growth and weight during medication, they have not provided definite results as to whether the reported growth and weight suppression are caused by medication or not. Such effects on growth are usually reported as minor, but there is substantial variability with some children being completely unaffected58,59,60 and others reporting significant growth suppression.35,61,62,63 There are many methodological limitations with these published studies and as a consequence it has not been possible to draw firm conclusions and poor growth has therefore remained a common public concern about the treatment of ADHD. Considering these gaps in our understanding and those expressed by the European Medicine Agency that we need more data about the long term effects of methylphenidate, the ADDUCE programme aimed to address scientific questions about the potential long term ("more than 1 year") adverse effects of Methylphenidate on growth and pubertal maturation in ADHD children and adolescents. The primary objective of the study, aimed to investigate the possible developmental adverse effects by stimulant medication in the long term has been achieved by a broad programme of work including: 1. A systematic review of evidence in the published literature: a systematic review has been performed and extensively updated up to August 2015 on the human literature focusing on the impact on growth and pubertal maturation of chronic MPH and stimulants exposure in...

Aim 4 i. Obtained Research Cabinet approval for IRBShare and worked with RIM, Human Subject Research Office, and legal counsel to adopt and sign contract for it.